bevacizumab,mirvetuximab
roche,Immunogen
['bevacizumab', 'ovarian', '$imgn']
check out $imgn - immunogen, inc. is showing a greater survival benefit in ovarian cancer patients not given bevacizumab. trading at $14.35 in healthcare/biotech. what do you think? #stockmarket #asco23 
Mathematician running a quant fund. Real-time performance updates and stock alerts from your favourite financial gurus  🦧